Presentation for FY2018 Consolidated Financial Results 
（624.1K）
Consolidated Financial Results for the Year Ended March 31, 2018 （195.0K）
Pharmaceutical Excipient “GRANFILLER-D®”Listed in “Japanese Pharmaceutical Excipients 2018”
Recognized as “2018 Certified Health & Productivity Management Outstanding Organization ~WHITE 500~”
Price Revision of Peracetic Acid Derivatives
Recovery and Operating Situation of Peracetic Acid Plant at Ohtake Plant(Fire Accident at Ohtake Plant: 5th Report)
Daicel to be responsible for marketing of Genomatica’s biobased 1,3-butylene glycol in Asia-Pacific （318.1K）
Outlook for Recovery of Peracetic Acid Plant of the Ohtake Plant (Follow-up Report)
Hitachi and Daicel Develop Management and Manufacturing Dashboard by Utilizing IoT to Integrally Visualize KPIs from Management Information to Manufacturing Workplaces’ Situations （299.4K）
Fire Accident at Ohtake Plant (Follow-up Report) （188.3K）
Apology for Fire Accident at Ohtake Plant （221.6K）
Collaborative Relationship and Capital Alliance With Toyoda Gosei （85.7K）
“3D-Ⅲ” — Our New Mid-Term Business Plan
Sept. 8, 2019
Daicel 100th Anniversary
